ADM (Chicago) has opened a new extrusion facility in Serbia that is set up to produce non-GMO soy proteins after the acquisition of SojaProtein less than a year ago.
“Our new extrusion facility not only increases the supply of locally sourced, non-GMO textured soy protein in Europe, which is in high demand, it also matches the pace of the incredible expansion of the meat alternatives category in the EMEA region,” said Leticia Gonçalves, ADM’s president of global foods, in a press release. “The growth in EMEA, showing a market value of $3 billion at the end of 2021 and an anticipated CAGR of 11.8% between 2021 and 2026, is astounding. With our 75+ years of experience developing tailored protein nutrition solutions now bolstered by both our expert colleagues at SojaProtein and our facility, we’re now even better suited to support our customers’ growth and innovation in the category.”
ADM will now offer both origination and extrusion capabilities, extending the non-GMO solutions currently available from SojaProtein. This is possible because 90% of the soy sourced is grown within 100 kilometers of the facility, enabling a local supply chain.
“In just under a year, our operational synergies with SojaProtein have made massive strides to meet demand for non-GMO soy protein,” Gonçalves said. “We’ll see continued growth with the broader protein solutions toolbox and improved R&D capabilities through the opening of our facility. The ingenuity of the new plant provides advanced extrusion and texturizing equipment, delivering optimized and flexible solutions, ultimately allowing for unmatched speed-to-market for our customers to create in-demand textured plant-based protein offerings with a delicious bite and chew.”
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.